摘要
目的 探讨子宫颈癌患者血清及组织中纤溶酶原蛋白激活物受体(uPAR)与子宫颈癌临床病理生理学特征的关系.方法 收集42例子宫颈癌ⅠB～ⅡA期患者的术前血清、癌组织及癌旁组织,30例健康人血清、30例子宫肌瘤患者的术前血清及术后子宫颈组织采用EHSA法进行uPAR测定.结果 子宫颈癌患者血清中uPAR含量明显高于对照及子宫肌瘤患者血清中uPAR含量;子宫颈癌患者血清中uPAR含量与肿瘤浸润程度、淋巴结转移有关,而与肿瘤分化程度无关;子宫颈癌患者癌组织中uPAR含量明显高于正常子宫颈组织中uPAR含量,与肿瘤分化程度有关,而与肿瘤浸润程度及淋巴结转移均无密切相关性.结论 子宫颈癌患者血清中uPAR含量与其侵袭、转移密切相关;组织中uPAR含量与其分化程度相关.
Objective To explore the relationship uPAR in tissue and plasma of patients with cervical carcinoma and its clinical pathophysiological characteristics. Methods The preoperative plasma cancer tissue and its adjacent tissue in 42 cases of patient with ⅠB～ⅡA cervical carcinoma and the preoperative plasma and postoperative cervical tissue in 30 cases of patient with hysteromyoma were collected. Their uPAR were detected by ELISA. Results uPAR in the plasma of patients with cervical carcinoma was significantly higher than those in healthy controls and in patients with hysteromyoma. It was related to tumor invasive depth and lymph node metastasis and not related to tumor differentiation, uPAR in cancer tissue of patients with cervical carcinoma was significantly higher than those in normal cervical tissue. It was related to tumor differentiation and not to tumor invasive depth and lymph node metastasis. Conclusion uPAR in the plasma of patients with cervical carcinoma is related to invasion and metastasis, uPAR in the tissue is related to tumor differentiation.
出处
《肿瘤研究与临床》
CAS
2008年第7期474-475,478,共3页
Cancer Research and Clinic
